- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07934173
Study of Oncology-Adapted Pain Reprocessing Therapy for Aromatase Inhibitor Associated Musculoskeletal Symptoms in Breast Cancer Survivors (PRT-BC)
A Single-Arm Pilot Study of Oncology-Adapted Pain Reprocessing Therapy for Aromatase Inhibitor Associated Musculoskeletal Symptoms in Breast Cancer Survivors
The goal of this study is to evaluate the feasibility, acceptability, and preliminary clinical effects of an oncology-adapted Pain Reprocessing Therapy (PRT) intervention for women with aromatase inhibitor-associated musculoskeletal symptoms (AIMSS). AIMSS is a common complication of aromatase inhibitor therapy for estrogen receptor-positive breast cancer and is associated with chronic pain, functional impairment, and premature discontinuation of endocrine therapy. The study will evaluate whether a six-session, manualized PRT intervention delivered remotely by trained palliative care therapists is feasible to implement and shows preliminary evidence of improving pain and physical function.
Studieöversikt
Status
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Inte tillämpbar
Kontakter och platser
Studiekontakt
- Namn: Jonathan Song
- Telefonnummer: 734-615-1279
- E-post: wmsong@umich.edu
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- History of ductal carcinoma in situ (DCIS) or Stage I-III estrogen receptor-positive breast cancer.
- Post-menopausal prior to starting AI or receiving luteinizing hormone-releasing hormone (LHRH) agonist therapy.
- Currently taking aromatase inhibitor therapy - anastrozole, exemestane, or letrozole - for adjuvant treatment of breast cancer or for chemoprevention.
- Current aromatase inhibitor therapy for at least 3 weeks and no more than 2 years prior to enrollment.
- Diagnosis of aromatase inhibitor-associated musculoskeletal symptoms (AIMSS), defined as new or worsening joint pain and/or myalgias since starting aromatase inhibitor therapy,
- Have had at least 3 months of recovery since the last invasive surgery
- Adequate home internet access, defined as reliable access to a private internet connection or cellular data service that supports real time two-way audiovisual telehealth visits using the University of Michigan-approved video conferencing platform on a computer tablet or smartphone. Participants must be able to complete study telehealth visits from a private location.
Exclusion Criteria:
- Evidence of active cancer or progression of disease on most recent imaging, confirmed with the treating oncologist.
- Planned invasive surgery during Day 0-60, that could interfere with study participation, pain assessment, or functional outcomes.
- Concurrent inflammatory arthropathy or autoimmune disorder.
- Patient self-report or EMR documentation of moderate to severe memory impairment or a dementia diagnosis as these would interfere with the ability to understand and remember key elements of the intervention.
- Current participation in cognitive behavioral therapy or other psychological therapy for pain, as concurrent pain-focused psychotherapy could confound interpretation of the effects of the study intervention. If they received psychotherapy in the past, they must be at least 30 days from their last session to enroll.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Stödjande vård
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Treatment Arm
PRT is a form of psychotherapy that incorporates pain neuroscience education (reframing chronic pain as a predominantly safe signal arising from the brain and nervous system rather than as something that only arises from damaged tissues) with mindfulness meditation and graded exposure strategies. . For this study, PRT has been adapted for the oncology and cancer survivorship context, and includes attention to cancer-related uncertainty, fear of recurrence, medical trauma, treatment-related bodily changes, and concerns about pain as a possible signal of cancer progression. The intervention is manualized and delivered over six sessions. |
All participants will be asked only to participate in six 30-45 min intervention sessions. Participants will need to complete the sessions in the order specified. PRT will be delivered remotely by trained palliative care therapists using a HIPAA compliant secure video conferencing platform. Each session will last approximately 30-45 minutes. The intervention will be delivered in English only. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Recruitment - Number
Tidsram: 11 months of recruitment activity
|
Number of approached patients who consent to participate. |
11 months of recruitment activity
|
|
Recruitment - proportion
Tidsram: 11 months of recruitment activity
|
Proportion of approached patients who consent to participate. |
11 months of recruitment activity
|
|
Retention - Assessments completed
Tidsram: 180 days
|
Mean number of post intervention assessments completed per subject; |
180 days
|
|
Retention - Proportion
Tidsram: 180 days
|
proportion of subjects completing the Day 60 and Day 180 assessments |
180 days
|
|
Intervention Uptake: PRT Sessions count
Tidsram: 60 days
|
Mean number of PRT sessions attended per subject |
60 days
|
|
Intervention Uptake: proportions of participants
Tidsram: 60 days
|
proportion completing at least 4 of 6 sessions and proportion completing all 6 sessions. |
60 days
|
|
Representativeness:
Tidsram: 11 months of enrollment activity
|
The demographic and clinical characteristics of enrolled participants vs. those of potentially eligible patients identified from the University of Michigan Rogel Cancer Center source population during the recruitment period. |
11 months of enrollment activity
|
|
Intervention fidelity.
Tidsram: 60 days of intervention
|
Intervention fidelity will be assessed through structured session checklists completed by interventionists after each visit, documenting delivery of required PRT components, session duration, and any deviations from the manual. |
60 days of intervention
|
|
Acceptability of PRT intervention
Tidsram: after 60 days of intervention
|
Treatment Acceptability and Adherence Scale (TAAS), a 10-item scale assessing perceived acceptability and usefulness of a behavioral intervention.(Milosevic et al., 2015) Scores above the midpoint - 35 out of 70 - will denote moderate acceptability of the intervention). |
after 60 days of intervention
|
|
Participant satisfaction
Tidsram: after 60 days of intervention
|
The CSQ-8 yields a total score ranging from 8 to 32, with higher scores indicating greater satisfaction. |
after 60 days of intervention
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Pain severity
Tidsram: up to 180 days
|
Pain severity will be measured using a 0-10 Numeric Rating Scale (NRS) assessing average pain over the prior 7 days, with anchors of 0 ("no pain") and 10 ("worst pain imaginable") (Jensen et al., 1986). |
up to 180 days
|
|
Change in Pain impact
Tidsram: up to 180 days
|
Pain impact will be assessed using the Pain, Enjoyment of Life, and General Activity (PEG) scale, a validated 3-item composite measure of pain severity and pain-related interference (Keller et al., 2004; Krebs et al., 2010). |
up to 180 days
|
|
Pain Interferece
Tidsram: up to 180 days
|
Pain interference will be assessed using the PROMIS Pain Interference Short Form 6b, a 6-item measure evaluating the extent to which pain interferes with daily activities, social participation, and enjoyment of life over the past 7 days |
up to 180 days
|
|
Physical Function T-scores
Tidsram: up to 180 days
|
Physical function will be measured using the PROMIS Physical Function 4a, a validated 4-item patient-reported measure of physical functioning. Scores will be converted to standardized T-scores, with higher scores indicating better physical function |
up to 180 days
|
Samarbetspartners och utredare
Samarbetspartners
Utredare
- Huvudutredare: Maria Silveira, MD, University of Michigan
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- UMCC 2026.079
- U54AG0923230 (Annat bidrag/finansieringsnummer: National Institutes of Health)
- HUM00292989 (Annan identifierare: University of Michigan Rogel Cancer Center)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Deidentified patient quantitative data and qualitative transcripts will be provided to a data repository at the University of Colorado which will gather the data on behalf of the National Institute of Aging.
Tidsram för IPD-delning
within 12 months of last participant completing study
IPD-delning som stöder informationstyp
- STUDY_PROTOCOL
- SAV
- ICF
- CSR
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .